Rapid genotyping of Toxoplasma gondii by pyrosequencing  by Edvinsson, B. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01661.x
Rapid genotyping of Toxoplasma gondii by pyrosequencing
B. Edvinsson1, M.-L. Darde´2, H. Pelloux3 and B. Evenga˚rd1, on behalf of the ESCMID Study Group on
Toxoplasmosis*
1Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Bacteriology,
Karolinska University Hospital Huddinge, Stockholm, Sweden, 2Laboratoire de Parasitologie-Mycol-
ogie, Faculte´ de Me´decine, Limoges and 3Parasitologie-Mycologie, De´partement des Agents Infectieux
and UMR CNRS-UJF 5163, CHU de Grenoble, Grenoble, France
ABSTRACT
Most human infections with the protozoan parasite Toxoplasma gondii are asymptomatic, but severe
symptoms can occur in immunocompromised patients, in developing foetuses, and in ocular infections
in immunocompetent individuals. The majority of T. gondii strains can be divided into three main
lineages, denoted types I, II and III, which are known to cause different clinical presentations. Simple
molecular methods with the capacity to discriminate rapidly among strains may help to predict the
course of infection and inﬂuence the choice of treatment. In the present study, real-time PCR followed by
pyrosequencing was used to discriminate among types I, II and III by analysis of two single nucleotide
polymorphisms in the GRA6 gene. Twenty-one isolates of T. gondii characterised previously were
analysed. Three different GRA6 alleles detected by the pyrosequencing technique identiﬁed types I, II
and III isolates correctly, while four atypical isolates possessed either the GRA6 allele 1 or the GRA6
allele 3. Reproducibility was 100%, and typeability, when including atypical strains, was 81%. It was
also possible to discriminate a mixture of two genotypes. The method was used to identify GRA6 type II
in blood and lung tissue from an allogeneic transplant recipient with toxoplasmosis.
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INTRODUCTION
Toxoplasma gondii is an obligate intracellular para-
site with worldwide distribution that commonly
infects warm-blooded animals, including humans.
Primary infections are usually asymptomatic, or
are characterised by mild, ﬂu-like symptoms.
When host immunity is acquired, the parasite
converts to a slow-dividing form, contained in
intracellular cysts, and establishes chronic infec-
tion. In general, the consequences of toxoplasmosis
can be severe in three clinical settings: reactivated
infections in immunocompromised patients; con-
genital infections; and ocular infections.
Multilocus analysis has demonstrated that
T. gondii has a population structure comprising,
at least in Europe and North America, three major
clonal lineages, denoted types I, II and III [1–3].
So-called atypical and recombinant strains exist,
but appear to be more frequent in other areas of
the world [4]. More than 50 different markers
have been described for typing T. gondii, with the
techniques used including multilocus enzyme
electrophoresis, restriction fragment length poly-
morphism analysis, random ampliﬁed polymor-
phic DNA PCR, microsatellite analysis and DNA
sequencing [4]. To a certain extent, the clinical
consequences of toxoplasmosis seem to depend
on the genotype of the infecting strain, in associ-
ation with the strain’s phenotype and the host’s
characteristics. Type II is responsible for most
cases of human toxoplasmosis, although types I
and III have also been detected [3,5–8]. Type I, or
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mixed genotypes I ⁄ III, has been identiﬁed in
severe cases of ocular toxoplasmosis in Brazil and
the USA [9,10]. However, more data concerning
the relationship between the genotype and the
clinical manifestations of toxoplasmosis should
be collected, and would improve our under-
standing of the connection between clinical
course, outcome and strain type. Furthermore,
strain genotyping may become increasingly
important in the developing ﬁeld of Toxoplasma
detection in food. Simple and rapid molecular
techniques are required to discriminate between
T. gondii strains.
In recent years, pyrosequencing has emerged as
a suitable technique for molecular genotyping of
various microbes by analysis of single nucleotide
polymorphisms (SNPs) [11–14]. Pyrosequencing
has been used previously to identify T. gondii
strains by analysis of the SAG2 gene, and to
discriminate among types I, II, III and mixed
genotypes in a sample [15]. A high degree of
polymorphism has been detected in the GRA6
gene of T. gondii, and this has been used to
discriminate among types I, II and III and atyp-
ical strains by sequencing techniques [4,16,17].
The present study describes a rapid molecular
approach, based on pyrosequencing of a fragment
of the GRA6 gene, and its application in the




The various laboratories of the ‘French parasitologist network
for Toxoplasma isolate collection’ (BRC ToxoBS group) have
collected a large series of T. gondii isolates from human
patients in France. Twenty-one T. gondii isolates provided by
the BRC ToxoBS group, characterised previously by multilocus
analysis, based on microsatellite and isoenzyme markers, were
used [18,19]: type I strains were RH, ENT, GIL, CT1 and ATIH;
type II strains were S3K, Pru, JONES, S1K-C, CHAM, Man-Nja,
SZY-C, GANGI, CHAMON and ELG; type III strains were C56
and NED; and atypical strains were TONT, P80, VAND and
RUB. DNA extraction was performed using a QIAamp DNA
mini Kit (Qiagen, Hilden, Germany) [20]. Extracted DNA was
quantiﬁed and its quality was controlled using a NanoDrop
ND-1000 Spectrophotometer (Nanodrop Technologies, Wilm-
ington, DE, USA) [21], with 80 fg of T. gondii DNA considered
to equal one genome [22].
Patient samples
A female patient, aged 63 years, with chronic myelogenous
leukaemia who subsequently relapsed after autologous trans-
plantation, was treated with allogeneic stem-cell transplanta-
tion. The patient was seropositive for T. gondii before trans-
plantation. Treatment with trimethoprim–sulphamethoxazole,
a commonly used prophylactic agent against toxoplasmosis,
was stopped because of skin rash. The patient reported
headache, and later developed fever and symptoms of an
upper respiratory tract infection, including cough. Magnetic
resonance imaging of the brain revealed a focal lesion. Blood
samples were taken on three consecutive days. The patient
died on day 3, and lung tissue was obtained at autopsy.
Real-time PCR
Primers and probes (Table 1) for real-time PCR ampliﬁcation
of T. gondii DNA and an internal ampliﬁcation control (IAC)
were designed using Beacon designer v.4.0 (Premier Biosoft
International, Palo Alto, CA, USA). Real-time PCR was
performed using a LightCycler 2.0 (Roche Diagnostics, Mann-
heim, Germany) with 20-lL sample volumes containing
uracil–DNA glycosylase (LightCycler FastStart DNA master
hybridisation probes; uracil–DNA glycosylase, heat-labile;
Roche Diagnostics). Human blood cell DNA (1 lg) was added
when T. gondii isolates were analysed. A 176-bp fragment of
the GRA6 gene of T. gondii was ampliﬁed using 500 nM
primers, 125 nM TaqMan probe and 2.4 mM MgCl2, with
2 min at room temperature, followed by 10 min at 95C and 50
cycles of 95C for 5 s and 65C for 30 s.
The pcDNA3 plasmid (Invitrogen, Parsley, UK) was used as
an IAC. A 265-bp fragment of the IAC was ampliﬁed using
125 nM primers (including the TaqMan probe) and the reaction
conditions described above. The amount of pcDNA3 plasmid
in a sample was balanced to a minimal detectable amount.
Standard curves were created to calculate ampliﬁcation
efﬁciency, error and the number of T. gondii genomes in
unknown samples [21]. Ampliﬁcation efﬁciency and error
were determined for real-time ampliﬁcation of the 176-bp
fragment of the GRA6 gene and the 265-bp fragment of the
IAC.
Pyrosequencing
Discrimination of T. gondii types I, II and III was achieved by
pyrosequencing analysis of two SNPs of the GRA6 gene
(accession numbers AF239283–AF239292). The variable nucle-
otides in the GRA6 gene occur at positions 162 and 171 [16]. An
Table 1. Primers and TaqMan probes used in real-time PCRs to amplify and detect a 176-bp fragment of the GRA6 gene of
Toxoplasma gondii, and a 265-bp fragment of the pcDNA3 plasmid used as internal ampliﬁcation control (IAC). A primer
complementary to the GRA6 fragment was used for pyrosequencing
Target Forward primer 5¢ ﬁ 3¢ Reverse primer 5¢ ﬁ 3¢ Probe 5¢ ﬁ 3¢
Real-time PCR GRA6 Biotin-TCGTCAATTCGTTGGGTGGA TGTATCATCTTCAGCTAACGAGTC FAM-CACCGCCCATCGCCGAAGAGTTG-BHQ1
Real-time PCR IAC TCGACTCTCAGTACAATCTG ATGGGCTATGAACTAATGAC HEX-TGCCGCATAGTTAAGCCAGTATCT-BHQ1
Pyrosequencing GRA6 – CGCAGCAGACAGCG –
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11-base fragment of the GRA6 gene (bases 162–172) was
analysed by pyrosequencing. A speciﬁc nucleotide dispersion
order was programmed according to the known GRA6
sequences. Nucleotides were dispersed into the reaction
mixture one at a time, so that incorporation of a complement-
ary nucleotide resulted in a peak. A ‘single peak’ corresponds
to a single base, and a ‘double peak’, which has greater
amplitude than a ‘single peak’, corresponds to two consecutive
identical bases. Pyrosequencing was performed using 0.35 lM
pyrosequencing primer in an MA96Q pyrosequencing instru-
ment (Biotage AB, Uppsala, Sweden) according to the instruc-
tions of the manufacturer.
Reproducibility (R) and typeability (T) of the pyrosequenc-
ing assay were determined by three independent analyses of
the 21 T. gondii isolates. R was calculated as R = Nr ⁄N, where
Nr = the number of isolates assigned the same type on repeat
testing, and N = the number of isolates tested. T, used as a
measure of the ability of the pyrosequencing assay to discrim-
inate between the different genotypes tested, was calculated as
T = Nt ⁄N, where Nt = the number of typeable strains, and
N = the number of isolates tested.
The ability of the method to detect more than one type in a
sample was also tested. The DNA concentrations in extracts of
RH (type I), ELG (type II) and NED (type III) were determined
by NanoDrop spectrophotometry, and DNA belonging to two
genotypes was mixed in 1:1 ratios. A mixture of RH, ELG and
NED DNA was also analysed to determine whether three
different genotypes could be detected in a sample.
RESULTS
In-vitro performance of real-time PCR
An ampliﬁcation efﬁciency of 2.0 is usually
considered to be a theoretical optimum [22]. For
ampliﬁcation of T. gondii DNA, the efﬁciency was
2.0, with error 0.01. The corresponding ﬁgures for
ampliﬁcation of the IAC were 1.56 and 0.07. The
sensitivity of the PCR was 100 T. gondii genome
equivalents in a reaction volume when the IAC
was included.
In-vitro performance of pyrosequencing
Pyrosequencing was successful with samples for
which real-time PCR was successful (100 genome
equivalents in a real-time PCR reaction volume).
Analysis of ampliﬁed non-biotinylated IAC frag-
ments alone did not result in pyrograms. The
technique of pyrosequencing allowed detection of
the three different alleles of GRA6, with R = 100%
(Nr = 21 and N = 21) for three independent runs
using 21 T. gondii isolates, and T = 81% (Nt = 17
and N = 21). Three different GRA6 alleles were
associated with types I, II and III (Fig. 1). Type I
was identiﬁed by G at position 162 and A at
position 171 (allele 1). The corresponding SNPs
were G and G (allele 2) for type II, and A and A
(allele 3) for type III. The four atypical isolates, as
deﬁned by multilocus analysis, possessed either
allele 1 (VAND and RUB) or allele 3 (TONT and
P80). As shown in Fig. 2, it was possible to detect
a mixture of two genotypes in a sample, but three
genotypes could not be distinguished.
Clinical application
Quantiﬁcation of T. gondii DNA in the patient
samples showed 3.7 · 103, 4.6 · 104 and 6.0 · 104
T. gondii genome equivalents ⁄mL blood, respect-
ively, on three consecutive days, and a large
amount of T. gondii DNA was found in the lung
tissue. Pyrosequencing analysis revealed GRA6
allele 2 in both blood and lung tissue, suggesting
infection by a type II T. gondii strain (Fig. 1d,e).
DISCUSSION
The present study illustrates the use of real-time
PCR and pyrosequencing to discriminate between
T. gondii isolates of types I, II and III, and also the
clinical application of the method. In this context,
real-time PCR can also be used to quantify and
monitor the amount of T. gondii DNA in patient
samples. This seems to have clinical relevance, as
the allogeneic transplant recipient died after a ten-
fold increase of parasite DNA in the blood over
the course of 3 days. Such cases highlight the
need for timely diagnostic procedures and aggres-
sive treatment of the infection following diagno-
sis. However, the extent to which the T. gondii
genotype affected the course of the infection
remains unclear, as host genetics, prophylactic
regimens, and also the condition of the immune
system, inﬂuence the outcome. Thus, T. gondii
genotypes should be determined for more cases of
toxoplasmosis in order to investigate the connec-
tion between genotype and the course and con-
sequences of the disease.
In a pyrosequencing assay described previ-
ously, two sets of primers were used for multiplex
ampliﬁcation of SAG2 DNA [15]. The pyrosequ-
encing assay described in the present study
required only one set of primers, and an IAC
could be included. Furthermore, the use of real-
time PCR decreased the analytical time signi-
ﬁcantly. However, the analytical sensitivity of
real-time PCR targeting the GRA6 gene, which
occurs in only one copy per parasite, did not
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Fig. 1. Pyrosequencing analysis of
the GRA6 gene of Toxoplasma gondii.
Pyrosequencing was performed by
addition of enzyme (E), substrate (S)
and a negative control (T). An
11-base fragment of the GRA6 gene
was sequenced; two single nucleo-
tide polymorphisms (SNPs), en-
closed in squares in the pyrograms
and underlined in the following
sequences, were analysed to dis-
criminate types I, II and III. The
sequence is: (a) GTGGTGTTAAG,
for type I; (b) GTGGTGTTAGG, for
type II; and (c) ATGGTGTTAAG, for
type III. Blood samples (d) and lung
tissue (e) from an immunocompro-
mised transplant recipient with
toxoplasmosis gave a type II isolate,





Fig. 2. Pyrosequencing analysis of
mixtures of Toxoplasma gondii types
I, II and III. Discrimination of mix-
tures of two different GRA6 alleles
required analysis of the presence or
absence of ‘single peaks’, and ana-
lysis of ‘single peaks’ with increas-
ing amplitudes towards ‘double
peaks’, or vice versa. A mixture of
two genotypes is indicated by the
presence of two different single nuc-
leotide polymorphisms (SNPs), e.g.,
A and G, and is written as A ⁄G. The
SNPs analysed are enclosed in
squares in the pyrograms, and are
underlined in the following se-
quences: (a) G ⁄ATGGTGTTAAG
indicates a mixture of types I and
III; (b) GTGGTGTTAA ⁄GG indicates
a mixture of types I and II; and (c)
G ⁄ATGGTGTTAA ⁄GG indicates a
mixture of types II and III.
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match the sensitivity achieved in studies utilising
repeated DNA targets, e.g., the 529-bp repeat
fragment or the B1 gene [7,21,22]. Consequently,
genotyping may fail if a more sensitive PCR
method has been used to detect the parasite and
only a low amount of T. gondii DNA is present
(personal unpublished observations).
Sequencing of the GRA6 gene has revealed
numerous SNPs [16]. The GRA6 pyrosequencing
assay presented here was designed to detect SNPs
at only two sites, and therefore does not have the
same typeability as would be achieved by sequenc-
ing longer fragments of the GRA6 gene. However,
it allowed correct identiﬁcation of isolates belong-
ing to the three main types of T. gondii that
predominate in Europe. Atypical strains were
identiﬁed as either type I or type III, and it was
concluded that analysis of several independent
genetic markers would be required if the aim was
to identify atypical strains [4,23]. The analytical
sensitivity of the assay might be increased by
targeting repeated DNA elements. This has been
done previously for PCR by analysis of the B1
repeat element [24]. However, repetitive DNA
elements are known to be highly polymorphic in
sequence among repeat units, which may lead to
confusing results.
Simultaneous detection of two different geno-
types was possible, but challenging. As shown in
Fig. 2, the absence or presence of a ‘single peak’
was indicative of type III, while discrimination of
types I and II relies on analysis of peak heights.
An SNP ﬂanked by different bases might be
preferred for this type of analysis, as this would
result in the simple absence or presence of ‘single
peaks’ when analysed by pyrosequencing, so that
the results would be easier to interpret. It was not
possible to detect three genotypes in a reaction.
These difﬁculties have been described previously
[15]. Nevertheless, the pyrosequencing assay pro-
vided a rapid and highly reproducible method to
discriminate between T. gondii types I, II and III.
Genotyping should be performed for more cases
of toxoplasmosis to draw further conclusions
concerning the inﬂuence of the precise T. gondii
genotype on the course and outcome of the
disease.
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